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A B S T R A C T
Hypercalcemia in HIV patients has been previously reported, but 1,25-(OH)2 vitamin D-mediated hypercalcemia,
due to increased activity of extrarenal 1-alpha hydroxylase, is rarely described with HIV-related infections or
malignancies. We describe a case of 1,25-(OH)2 vitamin D-mediated hypercalcemia in a patient presenting with
progressive cognitive decline and weakness. Initial evaluation revealed a new diagnosis of HIV, for which he was
started on antiretroviral therapy (ART). He was also noted to have mild asymptomatic hypocalcemia, likely from
his acute illness and malnutrition, which was not further investigated at the time. While the patient's mental
status initially improved with ART, he became progressively delirious and was found to be hypercalcemic ap-
proximately 4 weeks after the initiation of ART. Possible etiologies for hypercalcemia were vigorously evaluated,
including granulomatous disease, infection, and malignancy, in the setting of suspected immune reconstitution
inflammatory syndrome (IRIS), due to recent initiation of ART. Infectious workup was unrevealing, but com-
puted tomography (CT) of the chest, abdomen, and pelvis revealed new extensive diffuse lymphadenopathy and
hepatomegaly, not present on admission studies. Cytology and flow cytometry of a liver biopsy specimen re-
vealed CD10 positive high-grade B-cell lymphoma. Chemotherapy was not pursued due to poor performance
status. Over the next week, spontaneous tumor lysis developed, and the patient expired. Postmortem, his 1,25-
(OH)2 vitamin D level returned as markedly elevated. Immunohistochemical staining of his liver biopsy tissue
showed strong expression of CYP27B1.
1,25-(OH)2 vitamin D-mediated hypercalcemia is uncommon in a patient with newly diagnosed HIV and, in
this case, was likely due to IRIS unmasking an underlying high-grade lymphoma and restoration of immune
function (including T-cells and cytokine production). This case emphasizes the importance of including ag-
gressive lymphomas, capable of progressing over days to weeks, in the evaluation of hypercalcemia in HIV
patients at risk for developing IRIS and the rapid dynamic changes in mineral homeostasis that can occur with
such an aggressive tumor in an immunocompromised host.
1. Introduction
Hypercalcemia is uncommon, occurring in 0.2 to 4% of the general
population, and is most often due to hypercalcemia of malignancy or
primary hyperparathyroidism (Tebben et al., 2016). Hypercalcemia in
HIV-infected patients has been previously described, although 1,25-
(OH)2 vitamin D-mediated hypercalcemia, due to HIV-related infections
or malignancies, is distinctly unusual. HIV-infected patients may pre-
sent with 1,25-(OH)2 vitamin D-mediated hypercalcemia in association
with immune reconstitution inflammatory syndrome (IRIS) (Murdoch
et al., 2007). IRIS is defined as the paradoxical clinical worsening of a
preexisting condition or the unmasking of a new condition, after the
initiation of antiretroviral therapy (ART), and is attributed to the re-
covery of the immune system, with both positive and negative out-
comes for the host (French, 2009). Prior case reports describe 1,25-
(OH)2 vitamin D-mediated hypercalcemia in IRIS-associated infections
caused by Mycobacterium tuberculosis and Mycobacterium avium complex
(MAC) (Tsao et al., 2009; Tsao et al., 2012). Hypercalcemia from IRIS-
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related non-infectious conditions such as lymphoma, however, have
not, to our knowledge, been reported.
Recent studies suggest that patients with HIV have an increased
incidence of presenting with non-Hodgkin or Hodgkin lymphoma
during the first 3 to 6months following the initiation of ART (Lanoy
et al., 2011; Jaffe et al., 2011; Yanik et al., 2013). In fact, 12% of pa-
tients studied in a large HIV-associated lymphoma cohort had pre-
sentations compatible with lymphoma in the setting of unmasking
lymphoma IRIS, defined as lymphoma diagnosed within 6months after
ART initiation with a ≥0.5 log reduction in HIV RNA (Gopal et al.,
2014). We describe a case of 1,25-(OH)2 vitamin D-mediated hy-
percalcemia due to rapidly progressive lymphoma within 4 weeks of
ART initiation in a patient with newly diagnosed HIV, whose viral load
demonstrated a 3-log reduction during that time period. Furthermore,
this patient's presentation was remarkable in that the rapid onset of
spontaneous tumor lysis, due to the high-grade lymphoma, negated the
initially symptomatic moderate hypercalcemia.
2. Materials and methods
For immunohistochemistry, sections were deparaffinized and rehy-
drated. Endogenous peroxidase was blocked with 3% hydrogen per-
oxide. Goat CYP27B1 antibody (1:50) or rabbit PTHrP antibody (1:100)
was applied to paraffin-embedded liver sections (1:50, overnight, 4C)
and was detected with biotinylated anti-goat secondary antibody, fol-
lowed by ABD peroxidase reagent (all antibodies were from Santa Cruz
Biotechnology, Inc., Santa Cruz, CA). 1-alpha hydroxylase expression
was visualized by diaminobenzidine substrate and hematoxylin coun-
terstaining. Skin sections were used as positive (goat CYP27B1 anti-
body, 1:50) and negative (normal goat serum) controls, respectively.
Deidentified normal liver biopsy sections were obtained as controls for
these studies from the University of California, San Francisco (UCSF)
Department of Gastroenterology through a protocol approved by the
UCSF Institutional Review Board. Normal skin biopsy sections were
obtained from the Department of Pathology and Laboratory Medicine at
the San Francisco Veterans Affairs Health Care System.
3. Case report
A 64-year-old man with a history of schizophrenia presented to a
local free clinic shortly after relocating from Turkmenistan to San
Francisco. His daughter reported that he had developed a productive
cough, slowed speech, mild confusion, generalized weakness, anorexia
and a 45-pound weight loss over the prior 5months. While he was
previously employed as a healthcare worker and independent in his
activities of daily living (ADLs), he had become gradually dependent on
others for assistance with ADLs and was now wheelchair-bound. A few
months prior to presentation, he was evaluated by a physician in
Turkmenistan to rule out a cerebrovascular accident and was diagnosed
with prior hepatitis B infection by core antibody positivity, as well as a
“nonspecific encephalopathy”. In the clinic, the patient was found to be
hypotensive (systolic blood pressure 70mmHg) and tachycardic [pulse
110 beats per minute (bpm)], and he was sent to the Zuckerberg San
Francisco General Hospital Emergency Department for further evalua-
tion of progressive cognitive and physical decline.
In the Emergency Department, the patient's vital signs included
temperature 36.7 °C, blood pressure 88/56mmHg, heart rate 112 bpm,
respirations 20/min, and oxygen saturation 98% without supplemental
oxygen. On physical examination, he was ill-appearing and cachectic
with temporal wasting and was oriented only to self. He exhibited
generalized weakness and was unable to sit up or stand without assis-
tance. Cardiopulmonary exam revealed rales at the left lung base. He
had no scleral icterus or oral thrush, and the remainder of his ex-
amination revealed normal heart, abdomen, skin, and joints.
Initial laboratory evaluation revealed that the patient was HIV an-
tibody positive. HIV parameters at admission included a CD4 cell count
of 46 cells/uL (ref 420–1250), CD4 percentage of 3% (ref 28–59) and
HIV viral load> 4million copies/mL. Complete blood count showed
white blood cell count 4.6 k/uL (ref 3.9–11.7), hemoglobin 8.9 g/dL
(ref (13.3–17.7), hematocrit 27.2% (ref 39.8–52.2), platelets 113 k/uL
(ref 150–400). Chemistry panel was notable for total serum albumin
corrected calcium of 7.9mg/dL (ref 8.6–10.5), with the remainder of
the chemistry panel normal, including a serum phosphate of 3.2mg/dL
(ref 2.5–4.5) and serum creatinine of 1.0 mg/dL (ref 0.7–1.3) (Fig. 1).
Liver function tests were normal. The patient's initial hypocalcemia was
not further evaluated at this time.
Admission imaging included a chest X-ray and CT for evaluation of
productive cough, which showed mild bibasilar consolidation. The
patient underwent diagnostic evaluation for tuberculosis, which was
negative by serial sputum AFB smears, cultures, and Gene Xpert®
testing. Broncho-alveolar lavage cultures grew Pseudomonas aeruginosa,
and he was treated with a 7-day course of levofloxacin.
Head CT was performed to evaluate declining mental status and was
negative for acute abnormalities. A subsequent brain magnetic re-
sonance imaging (MRI) revealed patchy areas of T2/FLAIR hyper-
intensity in the periventricular and right frontal subcortical white
matter, as well as confluent white matter hyperintensity in the bilateral
occipital lobes, without associated enhancement or diffusion abnorm-
alities. Cerebrospinal fluid (CSF) examination was negative for oppor-
tunistic pathogens, including negative cryptococcal antigen testing and
John Christopher [JC] virus polymerase chain reaction (PCR). Altered
mental status was attributed to HIV encephalopathy. Additional
Fig. 1. Serum total calcium (mg/dL), phos-
phorus (mg/dL), uric acid (mg/dL), and creati-
nine (mg/dL) (upper panel) and CD4 cell count
(cells/mL), CD4 percentage, and viral load (co-
pies/mL) (lower panel) during the patient's
38 days of hospitalization.
For reference, CD4 cell counts were 46 cells/ml
and 43 cells/ml on days 2 and 33, respectively
(ref 420–1250). CD4% were 3% and 7% on days
2 and 33, respectively (ref 28–59). Viral loads
were 4,002,666 copies/mL, 24,132 copies/mL,
and 1317 copies/mL on days 3, 15, and 33, re-
spectively.
Abbreviations: ART, antiretroviral therapy;
PTH, parathyroid hormone; PTHrP, PTH-related
protein; AMS, altered mental status; TLS, tumor
lysis syndrome; VL, viral load.
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workup for opportunistic pathogens included negative acid-fast bacilli-
specific blood cultures and negative fungal markers. ART with standard
therapy doses of tenofovir alafenamide, emtricitabine, and dolutegravir
was started on hospital day 6, after CNS opportunistic infections had
been excluded. Appropriate prophylaxis for opportunistic infections,
including daily fluconazole for Cryptococcus prophylaxis, was also in-
itiated. Abdominal CT angiography was performed to assess for cir-
rhosis and showed normal liver size and contour, without evidence of
cirrhosis, but revealed 2 subcentimeter lesions, thought to be benign
(LI-RADS classification 2). A psychiatric consultant diagnosed bipolar
disorder, rather than schizophrenia, and he was treated with olanza-
pine. With these interventions, the patient's mental status markedly
improved by hospital day 9. He became more oriented, conversant with
his family, and cooperative with providers. His albumin-corrected
serum total calcium also improved on ART to 9.7 mg/dL (Fig. 1).
The patient remained hospitalized, awaiting discharge to a re-
habilitation facility. By hospital day 15, his HIV viral load had de-
creased to 24,132 copies/mL. On hospital day 28, his mental status
worsened, and he became progressively more impulsive, agitated, and
delirious. Laboratory testing now demonstrated an elevated albumin-
corrected serum total calcium of 13.0 mg/dL, confirmed by elevated
ionized calcium of 1.59mM (ref 1.12–1.32). Lactate dehydrogenase
(LDH) level was high at 850 U/L (ref 110–210), and serum creatinine
rose to 1.53mg/dL (ref 0.7–1.3)] (Fig. 1). Plasma intact parathyroid
hormone (PTH) was undetectable [< 6.3 pg/mL (ref 14–72)], serum
PTH-related protein (PTHrP) was 2.4 pmol/L (ref 0–2.3), serum 25-OH
vitamin D was low at 8 ng/mL (ref 30–80), and the serum 1,25-(OH)2
vitamin D level not available at this time later returned as markedly
elevated to 138 pg/mL (ref 19.9–79.3) (Fig. 1). Additionally, liver
function tests were newly elevated [aspartate aminotransferase (AST)
168 U/L (ref 10–48), alanine aminotransferase (ALT) 171 U/L (ref 10-
40), alkaline phosphatase 1093 U/L (ref 56–119), total bilirubin
5.3 mg/dL (ref 0.1–1.1), and direct bilirubin 4.0mg/dL (ref 0.1–0.3)].
Due to increasing serum creatinine, the patient's hypercalcemia was
initially treated with intramuscular calcitonin injections (administered
at a dose of 4 units/kg) on hospital days 36 and 37. Possible etiologies
of hypercalcemia, including granulomatous disease, infection, and
malignancy, were evaluated in the setting of presumed IRIS due to re-
cent initiation of ART. The entire serologic workup for opportunistic
infections was repeated and remained negative. HIV parameters were
rechecked and showed a CD4 T lymphocyte count of 43 cells/uL, CD4
percentage of 7%, and HIV viral load of 1317 copies/mL.
Renal ultrasound was performed to assess etiologies for acute
kidney injury and incidentally revealed 2 large, complex hepatic le-
sions. CT of the abdomen and pelvis now showed new bilateral pleural
effusions and extensive diffuse lymphadenopathy, including a large
area of hypoattenuation in the liver, suggestive of an infiltrative process
(Fig. 2). Cytology and flow cytometry of a liver biopsy specimen re-
vealed CD10 positive lymphocytes, compatible with a high-grade B-cell
lymphoma. Based upon these findings, an unmasking lymphoma IRIS
was diagnosed, and the patient was evaluated by oncology consultants.
The consensus was that his performance status was too poor to undergo
chemotherapy, and his family decided to focus his care on comfort
measures only.
During the next week, the patient developed spontaneous tumor
lysis syndrome, and corrected serum calcium fell from 13 to 11mg/dL
without any treatment. Serum phosphate rose to 4.3 from 2.6mg/dL,
and serum uric acid and LDH became elevated to 12mg/dL (ref
3.5–8.5) and 987 U/L (ref 110–210), respectively, and the patient ex-
pired shortly thereafter.
To investigate the source of the markedly elevated serum 1,25-
(OH)2 vitamin D level, immunostaining of liver tumor sections and
other control tissues was performed using a CYP27B1, 1-alpha hydro-
xylase, antibody, as previously described (Bikle et al., 2018). Positive
control was a normal skin biopsy, and negative controls were sections
from normal liver biopsies from HIV positive and HIV negative, nor-
mocalcemic subjects as described in Materials and Methods. Strong
expression of 1-alpha hydroxylase was evident in the lymphocytes of
the liver tumor compared to absent staining in normal control liver
biopsy (Fig. 3). Additionally, the lymphocytes did not stain for PTHrP.
Strongly positive staining of the skin biopsy for 1-alpha hydroxylase
was also noted, confirming the specificity of the immunostaining pro-
cedures, since this protein is known to be strongly expressed there.
4. Discussion
Hypercalcemia in HIV-infected patients is uncommon, with one
study of 66 patients reporting an incidence of only 2.9% (Peter, 1992)
with the most common etiologies identified as granulomatous diseases
and malignancies. Hypercalcemia associated with high 1,25-(OH)2 vi-
tamin D levels is typically due to the increased and unregulated activity
of extrarenal 1-alpha hydroxylases in ectopic sites, resulting in over-
production of 1,25-(OH)2 vitamin D from 25-(OH) vitamin D.
Risk factors for IRIS in this case included nadir CD4 T lymphocyte
count< 100 cells/uL and a plasma HIV viral load decrease of 2.5 logs
at the time of IRIS, compared with levels before ART initiation (Manabe
et al., 2007). A recent study suggested higher odds for developing IRIS
with the initiation of contemporary more potent HIV regimens versus
older treatments (Perez-Rueda et al., 2017). Conditions associated with
IRIS after the initiation of ART can lead to 1,25-(OH)2 vitamin D-
A. B. 
Fig. 2. Abdominal imaging during the patient's hospitalization.
A: CT angiography of the abdomen on admission showed two subcentimeter, low density lesions with no lymphadenopathy.
B: CT of the abdomen and pelvis after 27 days of ART showed new extensive diffuse lymphadenopathy (arrows), including a large area of hypoattenuation in the liver
(circled).
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mediated hypercalcemia and, in most cases, are attributable to oppor-
tunistic infections. Case reports have described 1,25-(OH)2 vitamin D-
mediated hypercalcemia, associated with mycobacterial infections in
HIV-infected patients, (Tsao et al., 2009; Tsao et al., 2012) and non-
infectious inflammatory conditions, such as sarcoidosis (Gomez et al.,
2000) and autoimmune thyroiditis and Graves disease (Jubault et al.,
2000), as well as the presentation of new malignancies.
Lymphomas are known to cause hypercalcemia, occurring in about
13% of non-Hodgkin lymphomas and 5% of Hodgkin lymphomas, due
to increased 1,25-(OH)2 vitamin D production in essentially all cases of
Hodgkin lymphoma and ~30–40% in non-Hodgkin lymphoma (Tebben
et al., 2016). In the remaining 60-70% of cases of non-Hodgkin lym-
phoma, hypercalcemia is mediated by PTHrP. In an older case series of
15 patients with lymphoma and hypercalcemia, seven of these patients
presented with elevated 1,25-(OH)2 vitamin D levels (Adams et al.,
1989). The types of lymphoma varied (B-cell, small noncleaved and
immunoblastic sarcoma 40%, follicular center cell 27%, Hodgkin 20%,
T-cell 13%). This study also included 4 patients with AIDS-associated
lymphoma. That series was reported in 1989, a time when highly ef-
fective ART was not available and included one patient with HIV-re-
lated lymphoma with a high 1,25-(OH)2 vitamin D level (Adams et al.,
1989). Further laboratory studies using lymphoma cells cultured from
the HIV-infected host showed that these cells had the capacity to me-
tabolize 25-(OH) vitamin D into a compound similar to 1,25-(OH)2
vitamin D by chromatography. Another case report described two pa-
tients with Burkitt lymphoma who presented with hypercalcemia and
suppressed PTH, although 1,25-(OH)2 vitamin D levels were not re-
ported (Spiegel et al., 1978). Recent studies have shown that patients
with HIV infection have an increased incidence of non-Hodgkin and
Hodgkin lymphoma during the first 3 to 6months of ART (Lanoy et al.,
2011; Jaffe et al., 2011; Yanik et al., 2013), the time-frame in which our
patient presented with his aggressive lymphoma and high tumor
burden. In a cohort of 482 patients with HIV-associated lymphoma,
approximately 12% of patients studied were found to have a course
compatible with IRIS unmasking the presence of a lymphoma, with 9%
of those patients (n=5) having Burkitt lymphoma (Gopal et al., 2014).
This patient initially presented with hypocalcemia, thought to be
due to acute illness, malnutrition and possibly vitamin D deficiency;
further evaluation was not pursued. He quickly developed hy-
percalcemia following the initiation of ART, along with rapid interval
presentation of high-grade B-cell lymphoma. Initial imaging studies of
the brain, chest, abdomen, and pelvis showed no sign of underlying
malignancy prior to ART initiation. Thus, lymphoma was thought to be
an unmasking phenomenon associated with immune reconstitution in
the setting of highly potent ART. We demonstrated strong im-
munostaining in the lymphocytes of his tumor for 1-alpha hydroxylase,
ectopically overexpressed by this B cell lymphoma, whereas staining for
PTHrP was absent in these cells. It has been reported that cytokines may
stimulate 1,25-(OH)2 vitamin D in B- and T-lymphocytes, with
CYP27B1 expression increased when these cells are activated (Bikle
et al., 2018). Other studies have shown that macrophages, after acti-
vation by cytokines such as interferon-ɣ (IFN-ɣ), stimulate 1-alpha
hydroxylase activity in granulomatous diseases (Seymour and Gagel,
1993). B-cell lymphomas have been shown to overexpress 1-alpha hy-
droxylase and be associated with hypercalcemia. Activated macro-
phages within the tumor itself are also thought to be involved in the
pathogenesis of lymphoma-associated hypercalcemia (Luceri and
Haenel, 2013). However, to date, none of these tumors was reported to
be associated with HIV-related IRIS. Multiple cytokines, including IFN-
ɣ, interleukin-18 (IL-18), and interferon-inducible protein 10 (IP-10 or
CXCL-10), have been found to be helpful as biomarkers for IRIS (Sereti
et al., 2010), although the time course of cytokine production as re-
flected in serum levels after the initiation of ART has not been firmly
established. Therefore, we postulate that T-cell derived cytokines may
Fig. 3. Immunostaining of sections from the liver tumor biopsy from the patient and from normal liver and skin biopsies from control subjects for detection of
Cyp27B1 or 1-alpha hydroxylase were completed as described in Materials and Methods. Bars= 50 μm.
A and B: Sections of the patient's liver tumor showed strong and diffuse staining for 1-alpha hydroxylase (brown) in the lymphocytes (solid arrow), but not in normal
hepatocytes (dashed arrow). Magnification is 20×.
C and D: Skin section from a healthy control subject in which the 1-alpha hydroxylase antibody was omitted from the incubation (negative control); skin section from
a healthy control subject showing positive (brown) immunostaining for 1-alpha hydroxylase in the epidermis. Magnification is 10×.
E: Section from liver biopsy from a HIV negative, normocalcemic control subject showed absent staining for 1-alpha hydroxylase. Magnification is 10×.
F: Section from liver biopsy from an HIV positive, normocalcemic patient showed absent staining for 1-alpha hydroxylase. Magnification is 10×. (For interpretation
of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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also play a role in activating lymphoma cells and macrophages leading
to 1,25-(OH)2 vitamin D-mediated hypercalcemia in patients with
lymphoma in the setting of IRIS. We also note that the patient received
fluconazole daily starting on hospital day 3 for Cryptococcus prophy-
laxis. Fluconazole is an inhibitor of 1-alpha-hydroxyalase and has been
shown to reduce levels 1,25-(OH)2 vitamin D (Sayers et al., 2015), so it
is possible that the elevation in the patient's 1,25-(OH)2 vitamin D level
may have been even more pronounced had he not been treated with
fluconazole.
We report this case because it dramatically unfolded over just
38 days. The patient initially presented with advanced AIDS along with
hypocalcemia, likely from severe malnutrition and illness. With the in-
itiation of ART inducing IRIS, his serum calcium normalized as he ra-
pidly developed marked tumor burden from a high-grade lymphoma
producing 1,25-(OH)2 vitamin D, leading to hypercalcemia. This is just
one form of hypercalcemia due to malignancy. He had no bone me-
tastases, and PTHrP and PTH levels were not elevated. Spontaneous
tumor lysis then ensued, common in rapidly growing lymphomas like
his, and serum calcium levels spontaneously decreased. This fall in
serum calcium (counteracting the high 1,25-(OH)2 vitamin D levels)
was likely driven by rising serum phosphorus levels characteristic of the
tumor lysis syndrome. Unfortunately, due to a tenuous functional
status, chemotherapy was not initiated because it was felt that he could
not tolerate it.
In conclusion, 1,25-(OH)2 vitamin D-mediated hypercalcemia,
driven by an increase in extrarenal 1-alpha hydroxylase expression, is
uncommon in patients with newly diagnosed advanced HIV. In our
patient, 1,25-(OH)2 vitamin D overproduction and hypercalcemia
emerged, likely due to the development of IRIS. IRIS, we speculate,
unmasked an underlying high-grade lymphoma as immune function (T-
cells and cytokine production) was restored. This case emphasizes the
importance of considering IRIS in a patient who has recently initiated
ART, because granulomatous infections and lymphomas are capable of
causing hypercalcemia, and aggressive lymphomas in the setting of IRIS
may progress rapidly (in just days) with ART initiation. This sequence
can result in marked effects on serum calcium homeostasis with clinical
consequences.
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